Table: Otsuka Holdings 6-MTH group results (IFRS)
Jul 31 (Reuters)-
Otsuka Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Jun 30, 2025 Jun 30, 2024 Dec 31, 2025
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 1.18 trln 1.11 trln 2.38 trln
(+6.5 pct) (+17.0 pct) (+2.2 pct)
Operating 242.12 126.28 450.00
(+91.7 pct) (-3.4 pct) (+39.1 pct)
Pretax
Net 173.53 107.80 330.00
(+61.0 pct) (+5.1 pct) (-3.8 pct)
EPS Basic 326.12 yen 198.61 yen 622.52 yen
Ann Div 120.00 yen 140.00 yen
-Q2 Div 70.00 yen 60.00 yen
-Q4 Div 60.00 yen 70.00 yen
NOTE - Otsuka Holdings Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug